Consumer Health · HealthTech & Digital Therapeutics · Brain & Mental Health · Metabolic Health · Women's Health & Longevity

I close deals for Family Offices, VCs, scale-ups and corporate innovation teams — across HealthTech, Consumer Health, Brain & Metabolic Health, Longevity and beyond.

Business Development leader — 14 years inside Merck, J&J, Unilever, Valenta & Askona Life. Now independent, closing enterprise partnerships, M&A exits, LP sourcing & innovation scouting. From London to LATAM, MENA, Africa, Eastern Europe & the Gulf. The deals actually close.

Built for Family Offices Scale-ups Corporates
See what I do → Book a discovery call
Kseniia Sholina
The Offer

Three types of clients, three curated offers

Each engagement starts with a scoped 90-day sprint that leads to a retainer. Transparent deliverables, transparent commercials, transparent exit clauses.

01
Capital

Family Offices

Multi-generational capital looking for returns in consumer health, healthtech & digital therapeutics, brain & mental health, and metabolic health — direct investments, co-investments & venture studio plays.

  • Investment-target scouting — monthly curated pipeline across 11 verticals (Mental & Brain Health · Cannabis · Psychedelics · Longevity · GLP-1 · Obesity · Diabetes · Sleep · Intimate Tech · Neuroscience)
  • Ecosystem relationships — warm ties to founders, VCs, accelerators & clinical KOLs across 5 continents
  • Idea & thesis scouting — new investment thesis validation & adjacent whitespace mapping
  • Venture building — stand up new ventures from zero with full operational ownership
  • AI-first deal flow — AI-powered scouting, GenAI due-diligence & AI-agent startup pipeline

For: Angel Investors · Single & Multi-Family Offices · UHNW direct investors

See the case: AmA Invest / Pink Elephant VC → See the case: Texera Systems →
02
Growth

Scale-ups

Fractional CBDO for revenue-stage founders preparing for the next stage. Own the BD + exit workstream end-to-end, 6–12 month engagements. Double your valuation from a PE exit to a strategic exit.

  • Strategic partnership pipeline — source, qualify & close enterprise deals with pharma, FMCG, insurers, retailers & digital health buyers
  • New revenue streams — design & launch adjacent monetisation (data licensing, white-label, B2B2C, SaaS, co-marketing)
  • Exit & M&A readiness — buyer landscape, valuation benchmarks, data room, pitch deck & warm acquirer pipeline (mySugr→Roche, Veri→Oura benchmarks)
  • Accelerator & CVC placements — curated fits into Bayer G4A, Plug & Play, Techstars & strategic CVC programs for pilots and intros

For: HealthTech, Wellness & Consumer Health scale-ups with $1M+ ARR

See the case: Sugar.no → See the case: Lóvi → See the case: The Coach / VAM Apps → See the case: 24TTL →
03
Innovation

Corporates

Designing the innovation funnel and attracting target startups. Managing strategic relationships. Shaping the innovation brief & strategy — plus launching and running the community around your corporate innovation agenda.

  • Innovation funnel design — from PoC to procurement in 90 days, compliance pathway pre-mapped (6 intros already delivered to Sanofi)
  • Curated startup scouting — pipeline matched to your innovation thesis across HealthTech, consumer health, brain & metabolic health verticals
  • Strategic relationship management — long-term relationships with founders, investors & KOLs across your target ecosystem
  • Brief & strategy formation — frame the innovation brief, set the thesis, define measurable success metrics
  • Innovation community — launch & run an internal or ecosystem community around your corporate innovation agenda
  • Joint events & co-hosting — roundtables, panels & founder dinners that bring your innovation team into the deal flow directly

For: Pharma · Consumer Health · Healthcare Data corporates with innovation mandates

See the case: Sanofi → See the case: Merck & Co (MSD Innovation Factory) →

Why me

15

Years in HealthTech & Big Pharma

Inside Merck, J&J, Unilever, Valenta & Askona — then building my own ventures at Lóvi, YoYo Mobility & Askona Ventures.

7

Years in pure Business Development

Closing $10M+ in white-label contracts · 8 medical-device deals signed · 35+ products launched · 2 FDA/CE certified.

6

Countries lived & operated

NL · UK · TR · PT · RU · FR. Based in London — Europe's financial capital — with active network in Saudi, Dubai, LATAM & the Gulf.

£100M+

In active client pipeline

Convergence Brain Health Fund (EUR 100M) · The Coach exit priming ($60–100M target) · Sugar.no pharma partnership · AmA Invest deal flow.

How I Work

Deal flow as a process, not a promise

Every engagement runs the same 3-phase process. Clear deliverables per phase. You can exit at any phase boundary.

01
Week 1

Discovery

Scope the engagement. Agree the commercials. Design the success metric.

  • 30-min diagnostic call · what you're closing, constraints, geography
  • Commercial model agreed (retainer + success fee)
  • Success metric defined (deals closed, capital raised, intros accepted)

Deliverable: Engagement proposal & kickoff plan

02
Weeks 2–4

Research

Map the market. Build the target list. Start warm outreach.

  • Market mapping & whitespace analysis (20–50 targets shortlisted)
  • Qualification & prioritization with signal rationale
  • Warm outreach begins · intro paths traced

Deliverable: Curated target list + rationale doc

03
Month 2+

Delivery

Warm intros land. Deals move forward. ROI tracked monthly.

  • 5–8 qualified warm intros per month
  • Negotiation & deal-structuring support
  • Monthly progress sync · pipeline dashboard · ROI report

Deliverable: Closed partnerships, tracked intros, monthly ROI

Book a discovery call → See who's already in the book
Recent Work

One case per persona — proof it works

Three live engagements that mirror the three Service cards above. Each with transparent deliverables, live metrics, and measurable results.

Capital · Family Office

AmA Invest / Pink Elephant VC

amainvest.co ↗

Deal flow, advisor matching, co-investor intros & venture building across Mental Health, Cannabis, Psychedelics & Longevity. Venture play: telemedicine for Treatment-Resistant Depression.

23advisors mapped (Sonas Pharma)
5+verticals covered
8portfolio cos covered
See the full case →
Growth · Scale-up

The Coach / VAM Apps

the.coach ↗

Fractional CBDO — corporate BD pipeline & exit priming. Double the valuation from a $30–40M PE exit to a $60–100M strategic exit over 12 months.

2×valuation uplift target
12moengagement scope
8buyers mapped & warm
See the full case →
Innovation · Corporate

Sanofi

sanofi.com ↗

Startup scouting on Metabolic Health brief + BD support for the HealthTech spinoff standing up in Paris. Curated founder pipeline matched to Sanofi's digital health thesis.

6curated intros delivered
3modelivery cycle
5+networking intros delivered
See the full case →
See all 11 case studies →
Why You Can Count On Delivery

Why the deals actually close

Advisory engagements fail when the advisor has never been the buyer, has never been the seller, or disappears after the target list is built. I've been both sides of every table — and the network is already running.

01

Operator, not advisor

14 years shipping — not consulting. 35+ products launched, 8 medical-device agreements signed, 11 white-label contracts closed ($10M total). I don't write decks for you — I close the deals you're trying to close.

02

Both sides of every table

Corporate innovation lead at Merck, J&J, Unilever, Valenta, Askona Life. Venture builder & co-founder at Askona Ventures, Lóvi and YoYo Mobility. I know what signs in pharma procurement AND what a scale-up founder needs to hear.

03

Network already warm

Not built-for-your-engagement — already running. Signed VC anchor (Convergence Partners · EUR 100M Brain Health Fund). Active FO book (AmA, Texera). Active pharma (Sanofi · 6 intros delivered). 9 deal-flow partners. Warm intros land week 1, not month 6.

04

Transparent scope · exit at any phase

Every engagement has a written deliverable per phase: engagement proposal → curated target list → closed partnerships. Measurable success metric agreed upfront. Exit at any phase boundary — no penalty. You pay for outcomes, not hours or decks.

One call. Clear scope. Transparent terms.

A 30-minute discovery call to see if we're a fit. No deck required — just tell me what you're trying to close. If it's a match, you'll have a scoped proposal within a week.

Book a discovery call →